Needham & Company analyst Mike Matson reiterated a Buy rating and $26 price target on Hologic (NASDAQ: HOLX) following news ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE